Retatrutide Clinical Trials
Every registered study, what it was designed to answer, and whether it has reported.
As of 24 October 2026, ClinicalTrials.gov lists 33 registered retatrutide studies: 13 Phase 1, 4 Phase 2, 15 Phase 3, and one pre-approval expanded access record. The programme began with a first-in-human study in 2019. Four Phase 3 trials have reported headline results; the longest-running, TRIUMPH-Outcomes, is not due to complete until February 2029.
The TRIUMPH programme — obesity and complications
TRIUMPH is the Phase 3 development programme. The initial registrational set comprised four global trials that began in 2023 and enrolled more than 5,800 participants between them. All four have now reported.
| Trial | Registry ID | Population | Enrolled | Status |
|---|---|---|---|---|
| TRIUMPH-1 | NCT05929066 | Obesity/overweight, no diabetes | 2,335 | Reported & published |
| TRIUMPH-2 | NCT05929079 | With type 2 diabetes | 1,152 | Topline reported |
| TRIUMPH-3 | NCT05882045 | Severe obesity with CVD | 1,946 | Topline reported |
| TRIUMPH-4 | NCT05931367 | With knee osteoarthritis | 445 | Topline reported |
| TRIUMPH-5 | NCT06662383 | vs tirzepatide, obesity | 800 | Not yet reported |
| TRIUMPH-6 | NCT06859268 | Maintenance of weight reduction | 643 | Due 2028 |
| TRIUMPH-7 | NCT07035093 | With chronic low back pain | 586 | Due 2027 |
| TRIUMPH-8 | NCT07232719 | Obesity/overweight, no diabetes | 250 | Due 2027 |
| TRIUMPH-9 | NCT07357415 | Dose-escalation schemes compared | 600 | Due 2028 |
| TRIUMPH-Outcomes | NCT06383390 | Cardiovascular & kidney outcomes | ~10,000 | Due Feb 2029 |
Two trials worth watching
TRIUMPH-5 is the only head-to-head comparison against tirzepatide in obesity. Until it reports, every retatrutide-versus-tirzepatide comparison in circulation is a cross-trial inference. TRIUMPH-Outcomes is the only trial powered to answer whether retatrutide changes cardiovascular and kidney outcomes. At about 10,000 participants and an event-driven design, it is the largest study in the programme.
Type 2 diabetes and liver disease trials
| Study | Registry ID | Design | Enrolled | Status |
|---|---|---|---|---|
| TRANSCEND-T2D-1 | NCT06354660 | vs placebo, diet and exercise alone | 537 | Completed |
| T2D vs semaglutide | NCT06260722 | Open-label, on metformin | 1,250 | Active, not recruiting |
| TRANSCEND-T2D-3 | NCT06297603 | Moderate/severe renal impairment | 320 | Active, not recruiting |
| MASLD/MASH master protocol | NCT07165028 | Multiple agents, liver outcomes | ~4,500 | Recruiting, due 2030 |
Phase 1 and Phase 2
Thirteen Phase 1 studies underpin the programme, beginning with NCT03841630, a single-ascending-dose study in 45 healthy participants that completed in 2019. Later Phase 1 work examined Japanese and Chinese participants, hepatic and renal impairment, drug–drug interaction with metoprolol, and comparability between manufactured versions of the molecule.
| Study | Registry ID | Population | Enrolled | Published |
|---|---|---|---|---|
| Phase 2 obesity | NCT04881760 | Obesity/overweight, no T2D, US only | 338 | NEJM, June 2023 |
| Phase 2 type 2 diabetes | NCT04867785 | vs placebo and dulaglutide | 281 | The Lancet, 2023 |
| Renal function study | NCT05936151 | Renal function endpoints | 146 | — |
| GZBF | NCT07467447 | Obesity/overweight | 300 | Recruiting |
The Phase 2 obesity trial is the foundation of the whole programme: 48 weeks, 338 participants, mean weight reduction of 17.5% at the 24-week primary endpoint and 24.2% at 48 weeks. Its lead investigator noted participants “had not yet reached a weight plateau” when it ended — which is why the Phase 3 trials ran for 68 to 80 weeks.
Expanded access
One record, NCT07629401, is a pre-approval expanded access entry listed with a status of “available”, last updated 3 August 2026, for obesity and obesity-related complications.
What we can and cannot say about it
We note this record because it exists on the public register. The record does not publish eligibility criteria or a participant pathway, and we are not affiliated with it. We are not describing it as a route of access, cannot advise on eligibility, and cannot make referrals. Expanded access programmes are operated by the sponsor and are normally initiated by a treating physician. Anyone with questions should raise them with their own doctor.
How to check any of this yourself
- Go to clinicaltrials.gov and search the molecule name, or paste an NCT identifier directly.
- Check Status — recruiting, active, completed or terminated.
- Read Outcome Measures — these are declared before results are known, which is what makes them meaningful.
- Check Sponsor and Study Design — randomised, masked, and against what comparator.
- Open Contacts and Locations for participating countries and sites.
- Note the last update date at the foot of the record.
For trials conducted in India, the national register is the Clinical Trials Registry – India at ctri.nic.in. Our guide to reading a trial record explains each field →